CTAD Lessons for 2020: More Phase 2 Trials, More Diversity

"Aaron Smith of Unlearn.AI, a startup company that uses machine learning to facilitate trials, suggested another way digital technology could cut enrollment. Machines can use data from the control arms of past trials to develop predictions for how disease will progress in a person depending on his or her baseline characteristics, he said. In effect, computers can generate a digital twin for each enrollee, describing what would likely happen to them without treatment. These digital twins can supplement the physical placebo group of a trial. This would lower the number of participants needed for a given trial, and allow a greater proportion of participants to receive drug rather than placebo. The chance of ending up in the placebo group deters many a potential participant."

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.
Blog

AD/PD 2021: Unlearn will present novel, AI-driven approaches to enabling smaller, more efficient Alzheimer’s clinical trials

Press

How Digital Twin Technology is Disrupting Healthcare

Press

Next-gen digital health innovation in clinical trials

The Rock Health team reflects on the evolution of digital in clinical trials, discuss the current state, and explore the opportunity to further transform drug discovery.
The use of digital twins in the healthcare industry is revolutionizing clinical processes.
Join us at The 15th​ International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, March 9 - 14, 2021.